Clinical Trial Update: A Study to Evaluate the Effect of VX-661 in Combination With Ivacaftor on Chest Imaging Endpoints in Subjects With Cystic Fibrosis, Homozygous for the F508del CFTR Mutation [Phase 2]

View source ↗

Summary

Phase 2 study evaluating VX-661 (elexacaftor) in combination with ivacaftor for chest imaging endpoints in cystic fibrosis patients homozygous for F508del CFTR;…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Cystic Fibrosis

Drugs mentioned

• Ivacaftor (ivacaftor)
• VX-661 (tezacaftor)

Snippet

Sponsor: Vertex Pharmaceuticals Incorporated | Conditions: Cystic Fibrosis | Phase 2 | Status: COMPLETED | Results posted: 2019-08-21